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Objective: The aim of our study was to determine the central and peripheral autonomic nervous 
system profiles underlying anorexia nervosa (AN) syndrome, given that affected patients present 
with the opposite clinical profile to that seen in the hyperinsulinism syndrome.
Design: We measured blood pressure and heart rate, as well as circulating neurotransmitters 
(noradrenaline, adrenaline, dopamine, plasma serotonin, and platelet serotonin), using high-
performance liquid chromatography with electrochemical detection, during supine resting, one 
minute of orthostasis, and after five minutes of exercise. In total, 22 AN patients (12 binge-eating/
purging type and 10 restricting type) and age-, gender-, and race-matched controls (70 ± 10.1% 
versus 98 ± 3.0% of ideal body weight) were recruited.
Results: We found that patients with AN had adrenal sympathetic overactivity and neural 
sympathetic underactivity, demonstrated by a predominance of circulating adrenaline over 
noradrenaline levels, not only during the supine resting state (52 ± 2 versus 29 ± 1 pg/mL) but 
also during orthostasis (67 ± 3 versus 32 ± 2 pg/mL, P , 0.05) and after exercise challenge 
(84 ± 4 versus 30 ± 3 pg/mL, P , 0.01).
Conclusion: Considering that this peripheral autonomic nervous system disorder depends on 
the absolute predominance of adrenomedullary C1 adrenergic nuclei over A5 noradrenergic 
pontine nucleus, let us ratify the abovementioned findings. The AN syndrome depends on the 
predominance of overwhelming adrenal sympathetic activity over neural sympathetic activity. 
This combined central and autonomic nervous system profile contrasts with that registered in 
patients affected by hyperinsulinism, hypoglycemia, and bulimia syndrome which depends on 
the absolute predominance of neural sympathetic activity.
Keywords: anorexia nervosa, adrenal sympathetic activity, adrenaline, noradrenaline, eating 
disorders
Introduction
Anorexia nervosa (AN) is a disorder of unknown etiology characterized by restricting 
eating and a relentless pursuit of thinness. There is a narrow range of age of onset (early 
adolescence), stereotypic presentation of symptoms and course, and relative gender 
specificity. Patients with AN and bulimia have a number of endocrine abnormalities 
which can be interpreted as adaptations to starvation.1,2
Individuals with AN have an ego-syntonic resistance to eating and a powerful pursuit 
of weight loss, yet are paradoxically preoccupied with food and eating rituals to the 
point of obsession. Individuals have a distorted body image and, even when emaciated, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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tend to see themselves as “fat”, express denial of being, and 
compulsively exercise to excess. They are often resistant to 
treatment, and lack insight regarding the   seriousness of the 
medical consequences of their disorder. In addition to the 
above, the relative contributions of psychologic and/or physi-
ologic factors to the appearance and development of the clinical 
symptoms included into the diagnostic criteria according to 
the Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) are not well defined. These criteria include 
two types of AN, ie, the restricting type, in which the person 
is not regularly engaged in binge-eating or pursuing behavior, 
and the binge-eating/purging type. Furthermore, individu-
als with AN display motor restlessness. We investigated the 
autonomic nervous system and   circulating neurotransmitters 
of 22 patients (12 binge-eating/purging type and 10 restricting 
type) referred to our institute for assessment, in an effort to 
find possible neuropharmacologic therapeutic strategies for 
this disease.
Methods
The study was conducted in accordance with the guidelines 
of the Declaration of Helsinki. Written informed consent was 
obtained after the purpose, nature, and potential risks had 
been explained to the subjects. The experimental protocol 
was approved by the ethical committee of the Fundación 
Instituto Medicina Experimental.
Patients
The study included 22 female AN patients (10 restricted 
type and 12 binge-eating type) and a group of age-, 
gender-, and race-matched controls. The diagnoses were 
made according to DSM-IV criteria. Mean age ± standard 
deviation (SD) of the AN patients was 22 ± 6.4 years and 
weight 70 ± 10.1% of ideal body weight, according to Met-
ropolitan Life Insurance Company tables. All patients and 
controls were extensively evaluated (physically, endoscopi-
cally, radiologically, biochemically, bacteriologically, and 
immunologically) in order to rule out any other physical 
illness. Exclusion criteria included pregnancy, lactation, 
smoking, and alcohol abuse. Neither patients nor controls 
took any medication for 15 days prior to the beginning of 
the study.
Measurement of blood pressure (BP) and heart rate (HR) 
as well as drawing of blood samples were performed simulta-
neously. Supine BP measurements were taken in a standard-
ized fashion using appropriate-sized cuffs and a random-zero 
mercury sphygmomanometer. All measurements were taken 
in accordance with a previously published protocol.3
Blood samples for plasma neurotransmitter   determinations 
were obtained simultaneously with BP and HR measurements 
through a heparinized catheter, inserted into the antebrachial 
contralateral vein 15 minutes before the first BP and HR 
measurements. Plasma noradrenaline, adrenaline, dopamine, 
free serotonin (f5-HT) and platelet serotonin (p5-HT) levels 
were measured during supine rest, one minute of orthostasis, 
and after five minutes of moderate exercise.3 All tests were 
performed on subjects after 10 hours of fasting. A physician 
in constant attendance noted any symptoms reported by the 
subjects.
Analytic methods
Noradrenaline, adrenaline, dopamine, plasma f5-HT, and 
p5-HT levels were measured. For all parameters, the samples 
were assayed in duplicate and all determinations were 
made simultaneously. We used reverse-phase, ion-pair high 
performance liquid chromatography with electrochemical 
detection for the measurement of monoamines. Optimization 
of chromatographic conditions and attainment of adequate 
quantification parameters allowed us to maximize sensitivity 
and reproducibility.
Blood for catecholamine and serotonin assays was 
transferred to plastic tubes, each containing 20 mg of eth-
ylenediaminetetraacetic acid (EDTA) and 10 mg of sodium 
bisulphite/mL in solution. The tubes were carefully inverted 
and placed on ice. The blood was promptly centrifuged at 
600 rpm for 15 minutes at 4°C in order to obtain platelet-rich 
plasma. Two milliliters of platelet-rich plasma, obtained for 
determination of p5-HT, were taken and stored at -70°C 
until assayed. The remaining blood was again centrifuged at 
7000 rpm. The supernatant, platelet-poor plasma, was divided 
into two portions for determination of catecholamines and 
f5-HT, after which the portions were stored at -70°C until 
assayed.
reagents and standards
Noradrenaline, adrenaline, dopamine, serotonin creatinine 
sulfate, dihydroxybenzylamine, sodium octyl sulfate, 
dibutylamine, acid-washed aluminum oxide, KH2PO4, 
  citric acid, and EDTA were purchased from Sigma-Aldrich 
(St Louis, MO). Microfilters were purchased from What-
man Inc.   (Florham Park, NY) through Merck SA, (Caracas, 
  Venezuela). Acetonitrile and 2-propanol were obtained from 
Merck SA. Glass-distilled water was deionized and filtered 
through a Millipore Milli-Q reagent grade water system 
  (Bedford, MA). Solvents were filtered through a 0.2 µm 
  Millipore filter and were vacuum de-aerated. Standard Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  solutions (1 mmo1/L) were prepared in 0.1 mo1/L perchloric 
acid and diluted to the desired concentration.
equipment
Liquid chromatography was performed using a Waters 
515 HPLC pump (Waters Milford, MA) equipped with a Rheo-
dyne valve injector 7125i, which was fitted with a 50 µL sample 
loop (Rheodyne; Berodine, Berkeley, CA). A 15 cm × 4.6 mm 
inner diameter Discovery C18 column packed with octadecyl 
silane 5 µm particles was preceded by a column prefilter of 
2 µm porosity, both from Supelco/Sigma-Aldrich. The detection 
system was a 460 electrochemical detector (Waters Corpora-
tion, Milford, MA). The potential of the glass carbon working 
electrode was set at ±0.61 V versus the silver–silver chloride 
(Ag-AgCl) reference electrode for detection of catecholamines 
and 0.70 V versus the Ag–AgCl for detection of indolamines. 
The chromatograms were registered and quantified using 
Empower software from Waters Corporation. The results were 
corrected for the volume of EDTA added.
Analytical assays
Plasma catecholamines
The assay was performed by extraction of the catecholamines 
onto 20 mg of alumina followed by elution with 200 µL of 
1.0 mo1/L HClO4 using regenerated cellulose microfilters of 
0.2 µm pore size purchased from Whatman Inc. We calibrated 
the instrument with standard plasma; after incubation with 
acid-washed aluminum oxide, a plasma pool of free cat-
echolamines was processed similarly to the plasma samples, 
but 20 µL of a standard solution of noradrenaline, adrenaline, 
and dopamine (50, 25, and 25 ng/mL, respectively) was 
added to the plasma pool. Both the standard plasma and the 
sample plasma were supplemented with 20 µL of internal 
standard (100 ng/mL of dihydroxybenzylamine). The mobile 
phase was KH2PO4 6.8045 g/L, EDTA 0.1 g/L, and di-N-
butylamine 100 µl/L. Sodium octyl sulphate was added as 
an ion-pair agent at a concentration of 0.6125 g/L, with 
the pH adjusted to 5.6. The flow rate was 0.4 mL/min. The 
sensitivities of this method for noradrenaline, adrenaline, 
and dopamine, respectively, were 6.4, 5.8, and 2.0 pg/mL. 
The intra-assay coefficients of variation were 2.8, 4.0, and 
4.0%, respectively. The interassay coefficients of variation 
were 6.7, 4.5, and 4.3%, respectively.
Plasma indolamines
After sonication of platelet-rich plasma to disrupt the plate-
lets (Ultrasonic Liquid Processor, Model 385; Heat Systems 
  Ultrasonics Inc., Farmingdale, NY), both   platelet-rich and 
  platelet-poor plasma were processed in the same way, ie, 200 µL 
of 3.4 mol/L perchloric acid and 50 µL of 5-  hydroxytryptophan 
solution (114.5 µg/mL) as internal standard, were added to 
1 mL of plasma vortexed and centrifuged at 10,000 rpm for 
15 minutes at 4°C. The supernatant was filtered through a 
0.22 µm membrane (Millipore) and 10 µL was injected into 
the column. Calibration runs were generated by spiking blank 
platelet-poor plasma with 50 µL of a solution containing 5-HT 
(10 µg/mL) and 50 µL of 5-hydroxytryptophan (114.5 µg/mL). 
This standard plasma was processed in the same manner as 
the samples. The mobile phase was citric acid 3.8424 g/L, 
sodium acetate 4.1015 g/L, EDTA 0.100 g/L,   di-N-butylamine 
100 µl/L, and 30 ml/L of 2-propanol. Sodium octyl sulphate 
was added as an ion-pair agent in a concentration of 4.25 mg/L 
with a pH of 5.0. The flow rate was 0.610 mL/min. The sen-
sitivity of the method for serotonin was 0.1 ng/mL. The 
  intra-assay coefficients of variation for p5-HT and f5-HT were 
6.2 and 8.7%, respectively.
Statistical methods
Results are presented as the mean ± standard error of mea-
surement (SEM). Multivariate one-way analysis of variance 
(ANOVA) with repeated measurements, and correlation 
coefficients (exploratory factor analysis) were used. Dbase 
Stats (TM) by Ashton Tate and Statview SE ± Graphics by 
Abacus were used for the statistical analysis.
Results
We did not find any significant differences between the two 
clinical types of AN in our patients.
cardiovascular parameters
Neither systolic BP nor diastolic BP showed significant 
variations during orthostasis or after moderate exercise in any 
group. However, differential pressure showed a significant 
increase during orthostasis in the AN group. HR showed 
significant and progressive rises during both orthostasis 
and exercise periods in the AN group but not in controls 
(Table 1).
catecholamines
Plasma noradrenaline showed significant and progressive 
increases during orthostasis and exercise in the two groups. 
However, the noradrenaline values and their increases were 
significantly higher in controls than in the AN patients. 
In addition, adrenaline showed important and significant 
increases during orthostasis and exercise in the AN patients, 
but not in controls. Plasma dopamine levels showed a Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  significant increase during orthostasis in AN patients but 
not in controls.
indolamines
p5-HT did not show any significant variation in any group. 
Plasma f5-HT, (ie, outside the platelets) showed mean basal 
values which were greater in AN patients than in controls 
and showed progressive and significant increases during 
orthostasis and exercise in AN patients but not in controls. 
Significant correlations amongst the different physiologic 
and neurochemical variables during rest, orthostasis, and 
after moderate exercise are shown in Table 2.
Discussion
The results presented in this study demonstrate that AN 
patients have adrenal sympathetic overactivity, as shown by 
the low noradrenaline:adrenaline plasma ratio registered dur-
ing orthostasis and exercise testing.4 The fact that falls in the 
noradrenaline:adrenaline ratio were opposed by systolic BP 
and HR rises fits well with the hypothesis that the basal adrenal 
sympathetic overactivity which underlies this syndrome was 
accentuated throughout the stress challenge. This adrenal 
sympathetic hyperactivity is responsible for the f5-HT rises 
also registered in these patients, and should be attributed to the 
increase in adrenaline plasma levels which provokes platelet 
aggregation,5 as revealed by the close positive correlation 
Table 1 Systolic blood pressure, diastolic blood pressure, heart rate, noradrenaline, adrenaline, dopamine, platelet-serotonin, and free 
serotonin blood values, at 0’ (resting), 1’ (orthostasis) and 5’ (post-exercise) in 22 patients with anorexia nervosa and their controls
0 minutes 1 minutes 5 minutes P values
0’ vs 1’ 0’ vs 5’ 1’ vs 5’
SBP  – An 152 ± 5 158 ± 3 171 ± 6 ,0.05* ,0.02* ,0.02*
– c 123 ± 5 124 ± 6 123 ± 2 n.s. n.s. n.s.
DBP  – An 60 ± 3 60 ± 2 61 ± 3 n.s. n.s. n.s.
– c 80 ± 4 77 ± 1 75 ± 3 n.s. n.s. n.s.
hr – An 71 ± 3 79 ± 4 83 ± 6 ,0.02** ,0.01** ,0.001**
– c 66 ± 2 67 ± 2 70 ± 4 n.s. n.s. n.s.
nA – An 166 ± 4 169 ± 5 175 ± 5 n.s. n.s. n.s.
– c 178 ± 2 202 ± 4 223 ± 5 ,0.05* ,0.01** ,0.01**
AD – An 52 ± 2 67 ± 3 84 ± 4 ,05* ,0.001*** ,0.001***
– c 29 ± 1 32 ± 2 30 ± 2 n.s. n.s. n.s.
DA – An 18 ± 1 21 ± 2 23 ± 2 n.s. n.s. ,0.05*
– c 17 ± 2 18 ± 2 19 ± 3 n.s. n.s. n.s.
p5-hT – An 228 ± 19 249 ± 22 225 ± 25 n.s. n.s. n.s.
– c 282 ± 21 292 ± 25 276 ± 30 n.s. n.s. n.s.
f5-hT – An 3.2 ± 1 13.7 ± 1 24.5 ± 2 ,0.001*** ,0.001*** ,0.001***
– c 2.99 ± 1 1.8 ± 1 3.3 ± 1 n.s. n.s. n.s.
Notes: results are expressed as mean ± SeM. *P , 0.05; **P , 0.02, ***P , 0.001. Most decimals were omitted. 
Abbreviations: AD, adrenaline (in pg/mL); An, anorexia nervosa; c, controls; DA, dopamine (in pg/mL); SBP, systolic blood pressure (in mmhg); DBP, diastolic blood 
pressure (in mmHg); HR, heart rate (in beats/minute) p5-HT, platelet serotonin (in ng/mL); f5-HT, free serotonin (in ng/mL); NA, noradrenaline (pg/mL); n.s., non significant; 
SeM, standard error of measurement.
Table 2 Significant correlations (r) for physiologic and plasma 
neurotransmitter parameters at 0 minutes (resting), one minute 
(orthostasis),  and  five  minutes  (post-exercise)  in  22  anorexia 
nervosa patients and their controls
SBP DBP HR NA AD DA p5-HT f5-HT
An 0 min
hr 0.61*
AD 0.66* 0.70*
DA 0.64*
f5-hT 0.70* 0.70*
c 0 min
hr 0.61*
An 1 min
hr 0.60*
AD 0.60* 0.69**
DA 0.63**
f5-hT 0.60* 0.69*
c 1 min
AD 0.60*
An 5 min
hr 0.70**
AD 0.75** 0.80***
f5-hT 0.66* 0.68*
Notes: *P , 0.05; **P , 0.02; ***P , 0.001.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; hr, 
heart  rate;  nA,  noradrenaline;  AD,  adrenaline;  DA,  dopamine;  p5-hT,  platelet 
serotonin; f5-hT, free serotonin.
between adrenaline and f5-HT levels seen in this study. In addi-
tion, we did not find significant physiologic or neuroautonomic 
differences between the two types of AN patients.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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These findings contrast with the enhancement of the 
noradrenaline:adrenaline ratio and diastolic BP rises regis-
tered in both controls and patients affected by hyperinsulin-
ism syndrome.6,7 We have demonstrated that this syndrome is 
associated with maximal enhancement of neural sympathetic 
activity and hypoglycaemia.6–9 These phenomena depend 
on both central and peripheral autonomic nervous system 
mechanisms. The former depends on A5 noradrenergic axons 
which inhibit C1 adrenergic medullary neurons, whereas the 
latter should be attributed to the direct inhibitory effect of 
sympathetic nerves at the adrenal gland level.10–13
The above findings are reinforced by the demonstration 
that a small oral dose of clonidine (an alpha-2 agonist) is 
able to reverse peripheral (plasma) noradrenaline:adrenaline 
ratio enhancement.14 It should be borne in mind that 
although the adrenergic medullary nuclei may also be 
inhibited by clonidine, this effect is only registered in mam-
mals with adrenal sympathetic overactivity (minimized 
noradrenaline:adrenaline plasma ratio). This effect can be 
attributed to the fact that although the drug is an alpha-2 
agonist (preferentially), it also acts at imidazole receptors 
which crowd adrenal medullary neurons but not A5 neu-
rons.15–22 These facts are reinforced by the observation that 
other imidazole agonists (rilmenidine, lofexidin) which do 
not act at the A5 neurons, display a powerful agonistic inhibi-
tory effect at the medullary nuclei.18–26
Some additional information helps to understand the 
central and peripheral autonomic nervous system interac-
tions which underlie the two opposite syndromes, ie, AN 
and hyperinsulinism. Oral glucose is absorbed at the small 
bowel and reaches the pancreatic beta cells which secrete 
insulin and send inhibitory drive (via gamma aminobutyric 
acid, GABA) to alpha cells. Plasma insulin crosses the 
blood–brain barrier and excites the A5 neurons,8,9 which send 
inhibitory axons to the adrenal medullary nuclei.10 Plasma 
glucagon also crosses the blood–brain barrier and excites 
the adrenal nuclei.27,28 At the peripheral level, sympathetic 
nerves which innervate alpha cells, but not beta cells, excite 
additional release of glucagon into the plasma. Finally, the 
A5 and the adrenal nuclei interchange inhibitory axons and, 
thus, predominance of A5 is responsible for neural sympa-
thetic activity, hyperinsulinism, hypoglycemia, and bulimia, 
whereas overactivity of the other neuroendocrine circuitry 
results in adrenal sympathetic hyperactivity, hyperglucago-
nism, hyperglycemia, and anorexia.29,30
With respect to all the above, it should be noted that 
although the thoracic sympathetic nerves that innervate 
pancreatic islet cells depend on the adrenal nuclei, lumbar 
sympathetic nerves which are responsible for muscular 
activity depend on the A5 pontine nucleus. This latter branch 
of peripheral neural sympathetic activity is responsible for 
circulating noradrenaline plasma levels.31–34 It should also 
be noted that the adrenal medullary nuclei are responsible 
for adrenal gland secretion which depends on thoracic 
sympathetic preganglionic axons.26 These nuclei receive 
excitatory axons from other pontomedullary nuclei (ace-
tylcholinergic, serotonergic, and glutamatergic), that are 
responsible for adrenal gland secretion, which is positively 
correlated with glucogenolysis and hyperglycemia.35 Special 
mention should be made about the excitatory drives which 
arise from the dorsal raphe 5-HT axons (highly associated 
with stress mechanisms and hyperglycemia), the abrogation 
of which with tianeptine (a serotonin uptake enhancer drug), 
is associated with reduction not only of serotonin but also 
of plasma adrenaline, glucagon, and glucose levels and, in 
addition, triggers increased insulin secretion.36–40 Thus, the 
hyperactivity of the C1 adrenal and dorsal raphe 5-HT axis 
should underlie the AN syndrome, which also includes raised 
plasma levels of both adrenaline and f5-HT.25,26,41
The gastric paralyzation and hypotony seen in AN patients 
contrasts with the fast gastric emptying and hypertony present 
in subjects affected by hyperinsulinism and hypoglycemia.6,7 
Radiologic investigation of these subjects always shows a 
hypertonic steer-horn stomach and an open pylorus which 
results in fast emptying.42 In addition, these patients also 
show increased plasma noradrenaline and decreased plasma 
adrenaline levels (very high noradrenaline:adrenaline plasma 
ratio), which is consistent with the predominance of neural 
over adrenal sympathetic peripheral branch.6
The understanding of the above-mentioned pathophysi-
ologic mechanisms enables adequate neuropharmacologic 
therapy for both disorders. Whereas patients affected by 
hyperinsulinism and hypoglycemia can be successfully 
treated with drugs that minimize neural sympathetic activity,7 
abrogation of the adrenal sympathetic branch by drugs which 
minimize the C1 adrenal medullary and dorsal raphe (5-HT) 
axis, eg, buspirone,41 amantadine,43,44 and/or tianeptine,36,37,45 
would be able to reverse clinical and radiologic symptoms 
in AN patients.26
At the peripheral level, AN patients showed raised levels 
of f5-HT and decreased levels of p5-HT. This is consistent 
with the increased platelet aggregation known to be triggered 
by overflow of adrenaline.46 Plasma f5-HT released from 
platelets inhibits insulin release from beta cells.47–50 In addi-
tion, plasma f5-HT, but not p5-HT excites the area postrema 
medullary nucleus (located outside the blood-brain barrier), Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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which is crowded with 5-HT3 excitatory receptors (Bezold 
Harish reflex).51,52 Excitation of this mechanism provokes 
vomiting that is suppressed by ondansetron (a 5-HT3 antago-
nist). The area postrema is the only 5-HT medullary nucleus 
which sends excitatory axons to the adrenal nuclei.53,54 Thus, 
these central and peripheral serotonergic mechanisms would 
be also annulled by amantadine. Finally, the C1 adrenal 
nuclei also receive glutamatergic excitatory drive from the 
hypothalamic area,55 that may be intercepted at this level by 
the drug, which explains its therapeutic effects based on the 
minimization of adrenal sympathetic hyperactivity.7,26,43 Our 
findings fit well with the decreased affinity of platelet alpha2 
receptors and an adrenaline inhibitory effect as demonstrated 
by Heufelder et al.56
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